Available with & without DeepDx® Viewer
6 Solutions
9 Products
An algorithm that automatically detects, segments and quantifies Ki-67 expression in breast cancer.
An Al model that performs segmentation and whole-slide scoring to provide measurements of ER receptor status in breast cancer. This algorithm allows pathologists to quickly and accurately identify breast cancer patients who are candidates for hormonal therapy, which can substantially improve their survival.
An Al model that performs segmentation and whole-slide scoring to provide measurements of PR receptor status in breast cancer. This algorithm allows pathologists to quickly and accurately identify breast cancer patients who are candidates for hormonal therapy, which can substantially improve their survival.
An Al model for the analysis of multiple (Prostate, Breast, Stomach, Lung) frozen-tissue types for cancer detection and segmentation.
An algorithm that analyzes WSis of breast core needle biopsies and excisional biopsies to detect breast cancer.
An Al model that detects cancer area on a digitized image of ovarian surgical biopsy specimen and predicts the presence of BRCA 1/2 mutations.
An Al model that aims to establish detailed standards to identify patients with NSCLC [Non-small Cell Lung Cancer] for treatment using c-MET inhibitors. As the algorithm detects and quantifies c-MET expression more accurately, it facilitates a decrease in inter-observer discrepancy among pathologists.
An advanced algorithm for segmentation and automatic IHC scoring of HER2 in breast cancer. The algorithm helps identify patients eligible for HER2 targeted therapy.
An algorithm for segmentation and automated PD-L1 scoring in NSCLC (Non-small Cell Lung Cancer).
At Deep Bio, we're at the forefront of transforming drug discovery through harnessing the full potential of data and AI. Our AI-enabled drug discovery solutions help guide biopharmaceutical companies in their quest to bring new drugs to market. DeepCDx combines state-of-the-art AI technology with a client-driven approach to develop purpose-built diagnostic solutions that accelerate the pace of discovery and drive innovation.
To Learn More Download
Our patented methods have been trained on thousands of cases to yield instantaneous and precise analysis of data.
Deep learning-based diagnostics
technology
Diagnostic result visualization
technology
Tissue slide indexing technology
Intelligent annotation technology
DeepDx Prostate won Silver at the Edison Award 2021 in the Cellular Research & Disease Prevention category.
Our research team won the first place in Camelyon17, a global image analysis competition for detection and classification of breast cancer lymph nodes metastasis.
Development of prediction models by combining cancer pathology image analysis with oncology clinical data.
DeepDx® Prostate is CE-marked, and MFDS-approved for clinical use in Korea. DeepDx® solutions are not cleared by the FDA and for Research Use Only (RUO) in the United States. Contact Deep Bio for more information on system configuration, functionality and indications for use.
